{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:57:07Z","timestamp":1787504227840,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-0957-7","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T05:07:19Z","timestamp":1530594439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Case report: a thiazide diuretic to treat polyuria induced by tolvaptan"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6511-5528","authenticated-orcid":false,"given":"Bart J.","family":"Kramers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maatje D. A.","family":"van Gastel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"issue":"14","key":"957_CR1","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477\u201385.","journal-title":"N Engl J Med"},{"issue":"8","key":"957_CR2","first-page":"1356","volume":"32","author":"CJ Willey","year":"2016","unstructured":"Willey CJ, Blais JD, Hall AK, Krasa HB, Makin AJ, Czerwiec FS. Prevalence of autosomal dominant polycystic kidney disease in the European Union. Nephrol Dial Transplant. 2016;32(8):1356\u201363.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"957_CR3","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ki.2014.120","volume":"86","author":"EM Spithoven","year":"2014","unstructured":"Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Caskey F, Collart F, Finne P, Fogarty DG, Groothoff JW, Hoitsma A, Nogier MB, Postorino M, Ravani P, Zurriaga O, Jager KJ, Gansevoort RT, ERA-EDTA Registry, EuroCYST Consortium, WGIKD, EuroCYST consortium, WGIKD. analysis of data from the ERA-EDTA registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. Kidney Int. 2014;86(6):1244\u201352.","journal-title":"Kidney Int"},{"issue":"25","key":"957_CR4","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med"},{"issue":"20","key":"957_CR5","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","volume":"377","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"957_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","volume":"65","author":"WE Boertien","year":"2015","unstructured":"Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Short-term effects of Tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis. 2015;65(6):833\u201341.","journal-title":"Am J Kidney Dis"},{"key":"957_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM196004142621501","volume":"262","author":"JD Crawford","year":"1960","unstructured":"Crawford JD, Kennedy GC, Hill LE. Clinical results of treatment of diabetes insipidus with drugs of the chlorothiazide series. N Engl J Med. 1960;262:737\u201343.","journal-title":"N Engl J Med"},{"issue":"4665","key":"957_CR8","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/183891a0","volume":"183","author":"JD Crawford","year":"1959","unstructured":"Crawford JD, Kennedy GC. Chlorothiazid in diabetes insipidus. Nature. 1959;183(4665):891\u20132.","journal-title":"Nature"},{"issue":"12","key":"957_CR9","first-page":"1005","volume":"58","author":"CW Havard","year":"1965","unstructured":"Havard CW. Thiazide-induced antidiuresis in diabetes insipidus. Proc R Soc Med. 1965;58(12):1005\u20137.","journal-title":"Proc R Soc Med"},{"key":"957_CR10","unstructured":"Anonymous Jinarc : European public assessment reports \u2013 product information. London, 2016 (Accessed 3 Aug 2017, at \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002788\/WC500187921.pdf\n                    \n                  ). ."},{"issue":"9","key":"957_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, eggers P, van Lente F, Greene T, Coresh J. CKD-EPI (chronic kidney disease epidemiology collaboration): a new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"1","key":"957_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, CRISP Investigators. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160\u201372.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"957_CR13","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2215\/CJN.08690813","volume":"9","author":"D Zittema","year":"2014","unstructured":"Zittema D, van den Berg E, Meijer E, Boertien WE, Muller Kobold AC, Franssen CF, de Jong PE, Bakker SJ, Navis G, Gansevoort RT. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol. 2014;9(9):1553\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"957_CR14","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1172\/JCI104657","volume":"41","author":"LE Earley","year":"1962","unstructured":"Earley LE, Orloff J. The mechanism of Antidiuresis associated with the Administration of Hydrochlorothiazide to patients with vasopressin-resistant diabetes insipidus. J Clin Invest. 1962;41(11):1988\u201397.","journal-title":"J Clin Invest"},{"issue":"10","key":"957_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrneph.2015.89","volume":"11","author":"D Bockenhauer","year":"2015","unstructured":"Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol. 2015;11(10):576\u201388.","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"957_CR16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.7326\/0003-4819-75-6-853","volume":"75","author":"MP Fichman","year":"1971","unstructured":"Fichman MP, Vorherr H, Kleeman CR, Telfer N. Diuretic-induced hyponatremia. Ann Intern Med. 1971;75(6):853\u201363.","journal-title":"Ann Intern Med"},{"issue":"2","key":"957_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1378\/chest.103.2.601","volume":"103","author":"M Sonnenblick","year":"1993","unstructured":"Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest. 1993;103(2):601\u20136.","journal-title":"Chest"},{"issue":"6","key":"957_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1751-7176.2008.08126.x","volume":"10","author":"SJ Mann","year":"2008","unstructured":"Mann SJ. The silent epidemic of thiazide-induced hyponatremia. J Clin Hypertens (Greenwich). 2008;10(6):477\u201384.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9569","key":"957_CR19","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet"},{"issue":"2","key":"957_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000046231","volume":"21","author":"T Ecder","year":"2001","unstructured":"Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol. 2001;21(2):98\u2013103.","journal-title":"Am J Nephrol"},{"key":"957_CR21","first-page":"gfx043","volume":"31","author":"VE Torres","year":"2017","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD, TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 trial. Nephrol Dial Transplant. 2017;31:gfx043.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"957_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","volume":"50","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol. 2007;50(2):213\u201322.","journal-title":"J Cardiovasc Pharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0957-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-0957-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0957-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:11:29Z","timestamp":1562094689000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-0957-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["957"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-0957-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"23 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RTG received research funding from IPSEN Farmaceutica, Otsuka and Sanofi-Genzyme for polycystic kidney disease research. All money was paid to his institution. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"157"}}